TAK TAKEDA Terminates Phase 3 Soticlestat Study in Dravet and Lennox-Gastaut Takeda has halted a Phase 3 trial of soticlestat in epilepsy patients previously exposed to fenfluramine, citing a business decision unrelated to patient safety.
